Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6597146 | 0.84 | MGAM (0.33) | KMT2A | |
| SCHEMBL22616086 | 0.80 | PAM (0.32) | — | |
| SCHEMBL24387394 | 0.80 | ALOX15 (0.36) | ALOX15HSD17B10LDHASRR | |
| SCHEMBL906211 | 0.80 | HTT (0.42) | ALOX15HSD17B10LDHASRR | |
| SCHEMBL14447112 | 0.79 | TSHR (0.40) | ALOX15HSD17B10 | |
| SCHEMBL9574931 | 0.79 | ALOX15 (0.31) | ALOX15HSD17B10 | |
| SCHEMBL9579111 | 0.79 | HMGCR (0.33) | KMT2ATET2 | |
| SCHEMBL22615636 | 0.78 | TSHR (0.31) | — | |
| SCHEMBL21123163 | 0.78 | — | — | |
| SCHEMBL1681694 | 0.77 | ALOX15 (0.34) | ALOX15HSD17B10TET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8398898-B2 | Soluble metal salts for use as conductivity promoters | DESIGNER MOLECULES, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8398898-B2 | Soluble metal salts for use as conductivity promoters | DESIGNER MOLECULES, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20090215940-A1 | SOLUBLE METAL SALTS FOR USE AS CONDUCTIVITY PROMOTERS | DESIGNER MOLECULES, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090215940-A1 | SOLUBLE METAL SALTS FOR USE AS CONDUCTIVITY PROMOTERS | DESIGNER MOLECULES, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | DUAN JINGWU (US) | 2004-04-15 | — | — | US | disclosed |
| EP-1263756-B1 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2003081212-A2 | ADJUSTABLE AIR SAMPLER WITH PSYCHROMETRICS FOR VIABLE AND NON-VIABLE AEROSOLS | PATHOGENUS, INC. (CA) | 2003-10-02 | — | — | WO | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-0424099-B1 | Method of Preparing Polymeric Compositions for Oxygen Permeable Contact Lenses | POLYMER TECHNOLOGY CORP (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5346978-A | Polymeric compositions useful in oxygen permeable contact lenses | POLYMER TECHNOLOGY CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| US-5177168-A | Copolymer of an unsaturated carboxylic acid ester | POLYMER TECHNOLOGY CORP. (US) | 1993-01-05 | — | — | US | disclosed |
| US-5032658-A | Hardness, unsaturated ester | POLYMER TECHNOLOGY CORPORATION (US) | 1991-07-16 | — | — | US | disclosed |
| EP-0424099-A2 | Method of Preparing Polymeric Compositions for Oxygen Permeable Contact Lenses | POLYMER TECHNOLOGY CORPORATION (US) | 1991-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | TNF, XPNPEP1, MMP2 | ALOX15 2071/4885HSD17B10 3073/4885KMT2A 1914/4885 |
| US-20090215940-A1 | SOLUBLE METAL SALTS FOR USE AS CONDUCTIVITY PROMOTERS | CTCF, CD44, SP1 | ALOX15 1653/4885HSD17B10 3524/4885KMT2A 654/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | ALOX15 2359/4885HSD17B10 3253/4885KMT2A 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.